Prophylactic HPV vaccines – an update

作者
Anne Szarewski
出处
期刊:Cytopathology [Wiley]
卷期号:18 (s1): 4-5
标识
DOI:10.1111/j.1365-2303.2007.00499_7.x
摘要

Cervical cancer affects nearly half a million women each year, and nearly half of them die. The greatest problem is in the developing world, though even in the UK nearly 3 000 women develop cervical cancer each year. Infection with certain types of sexually transmitted human papillomavirus (HPV), in particular HPV 16 and HPV 18, is the main cause of cervical cancer. It has been shown that 99.7% of cervical cancers contain HPV DNA. Infection with HPV appears to be extremely common in young people, but is usually transient. It appears that the presence of HPV is more meaningful in older women (over 30), who have persistent infection. Screening tests detect cellular abnormalities early, but the ultimate solution to a viral disease is obviously a vaccine. A problem is the number of cervical cancer HPV types which need to be included (potentially 15). Two vaccines have proved extremely effective in clinical trials, with recent results demonstrating 100% efficacy against persistent HPV infection and development of CIN up to five years of follow up (Harper 2006, Villa 2005). One of these (Gardasil, recently licensed) contains four HPV types and would thus protect against genital warts (types 6 and 11) as well as the commonest cervical cancer HPV types (16 and 18). Gardasil ® is licensed for children and adolescents aged 9 to15 years and adult females aged 16 to 26 years. The NHS cost of one dose of the vaccine is £80.50, three doses are required to provide protection. In clinical trials Gardasil ® showed 100% (95% CI 92.9 – 100) efficacy in the prevention of CIN2/3 related to HPV 16 and 18. Gardasil ® was also 100% (95% CI 41.4 – 100) effective in preventing VIN2/3 related to HPV 16 and 18. In addition, there were no cases of high‐grade vaginal lesions (VaIN2/3) due to HPV types 16 and 18 in those who received Gardasil ® , compared to five in those who received placebo (not statistically significant). Gardasil has shown 98.9% (95% CI 93.7–100) efficacy in the prevention of genital warts related to HPV types 6 and 11 (Siddiqui & Perry, 2006). The other vaccine (Cervarix) contains types 16 and 18, and thus targets cervical cancer alone. Recent data (Harper 2006) have suggested a degree of cross‐protection, against HPV types 31 and 45, which are phylogenetically related to types 16 and 18. If confirmed, this would significantly increase the level of protection afforded by the vaccines. There are still a number of questions to which we do not have answers. We do not know at present how long the immunity conferred by these vaccines lasts: ideally, such a vaccine would be administered with other childhood vaccines, removing any link with sexual activity in the minds of parents. However, that would depend on the immunity lasting for decades, or boosters being given. At present, it is envisaged that the age group between 11 and 12 is probably going to be the target, and indeed, this is what has been recommended in the US. But should we not vaccinate boys as well as girls? If we eliminate cancer due to HPV types 16 and 18, will other types take their place? Will we need different vaccines for different populations? What might be the effect of a vaccine in HIV positive women? There are no answers to these questions at present. A fundamental issue underpinning the potential resistance to an HPV vaccine is the lack of education of both the public and health professionals about HPV. Possibly the most important aspect will be how the information is presented, and work needs to be done to ascertain the most effective ways of doing this. This has been a woefully neglected aspect of strategies proposed for the introduction both of HPV testing and vaccines. In theory, an HPV vaccine could prevent almost all cervical cancer, eventually removing the need for cervical smears. However, there is at least one whole generation of women for whom the vaccine will come too late, and who will continue to require screening. Also, until the number of HPV types in the vaccine is increased, there will still be cancers not prevented by vaccination. The exact point at which vaccination supersedes screening will depend upon the percentage of cancers preventable by the vaccine, the percentage being prevented by the screening programme in place, the attitude of women to having smears and the attitude of the society in which they live to vaccination against a sexually transmitted virus. It is therefore clear this will vary considerably. References: Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli‐Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomized control trial. Lancet 2006; 367(9518): 1247–55. Rosenthal SL, Stanberry LR. Parental acceptability of vaccines for sexually transmitted infections. Archives of Paediatrics & Adolescent Medicine 2005; 159 (2): 190–2. Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66: (9): 1263–73. Szarewski A. Prophylactic vaccines for HPV: a bright future for cervical cancer prevention. J Med Screening 2005; 12: 163–5 Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis‐Johannessen G, Andersson‐Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up. Br J Cancer. 2006; 95:1459–66

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luyang发布了新的文献求助10
刚刚
刚刚
刚刚
博丽灵梦发布了新的文献求助10
1秒前
sanshanake发布了新的文献求助10
2秒前
快乐土豆发布了新的文献求助10
2秒前
葫芦侠发布了新的文献求助10
2秒前
梦醒花犹存完成签到,获得积分10
2秒前
3秒前
鱼鱼完成签到,获得积分10
3秒前
4秒前
干净以南发布了新的文献求助10
4秒前
无情百褶裙完成签到 ,获得积分10
4秒前
搜集达人的应助被White采纳,获得10
4秒前
米月发布了新的文献求助10
4秒前
SongYE发布了新的文献求助10
4秒前
Owen的应助被路宽宽采纳,获得10
5秒前
hsialy完成签到,获得积分10
5秒前
酷波er的应助被范特西采纳,获得10
6秒前
嘿嘿哒发布了新的文献求助30
6秒前
hgy发布了新的文献求助10
7秒前
7秒前
MillieWang发布了新的文献求助10
8秒前
8秒前
WWW完成签到,获得积分10
9秒前
15022655822完成签到,获得积分10
9秒前
9秒前
12秒前
13秒前
13秒前
斜风细雨必须归完成签到,获得积分10
14秒前
英姑的应助被lalalac采纳,获得10
14秒前
科研通AI6.4的应助被胡萝卜卜采纳,获得10
15秒前
科研通AI6.3的应助被yyyy采纳,获得10
15秒前
tuanheqi发布了新的文献求助20
16秒前
脑洞疼的应助被Rina采纳,获得10
16秒前
苹果梦蕊发布了新的文献求助10
16秒前
17秒前
17秒前
共享精神的应助被zima采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193079
求助须知:如何正确求助?哪些是违规求助? 9579384
关于积分的说明 21865064
捐赠科研通 7792635
什么是DOI,文献DOI怎么找? 3437158
关于科研通互助平台的介绍 2560661
邀请新用户注册赠送积分活动 2483960